58) for fatal myocardial infarction, 1
To evaluate the comparative cardiovascular adverse outcomes, such as venous thromboembolism, heart failure, angina, myocardial infarction and stroke in patients with
Currently, tamoxifen is the most commonly used and very effective agent as adjuvant therapy for the treatment of breast cancer
2 However, their safety has been a con-tentious issue, with some meta-analyses of random-ized controlled trials (RCTs) reporting an increased risk of
People with higher levels of niacin in their blood may be more at risk of a heart attack or
Tamoxifen is used mainly to treat hormone receptor-positive breast cancer (breast cancer with cells that have estrogen and/or progesterone receptors on them)
Cardiovascular diseases increased in incidence rapidly in women older than 60 years
Background: The overall effect of prophylactic tamoxifen in women depends on the balance between the effects of the drug, which include preventing breast cancer and altering cardiovascular risk
These findings are in contrast to recent reports of increased C-reactive protein associated with postmenopausal estrogen
The influence of tamoxifen on plasma lipids and lipoproteins was monitored in 46 postmenopausal and 8 premenopausal women treated for advanced breast cancer up till 6 months
7 In comparison with placebo, the use of tamoxifen resulted in: reduced risk of invasive breast cancer (Relative Risk – RR = 0
Since randomized clinical trials conducted in Scotland and Sweden to test the efficacy of tamoxifen treatment in breast cancer patients have suggested that this drug may also reduce the risk of coronary heart disease, Costantino et al
07–1
54664
Patients: Clinically postmenopausal women (140) with a diagnosis of axillary
Pain
82 vs 35
Similar patterns were seen for other cardiovascular outcomes Breast cancer remains the most common female malignancy in the United States
It is therefore important to understand the effect of hormone therapies on
It is important to establish the risk period for VTEs to formulate guidelines for prescribing tamoxifen and monitoring for cardiovascular events in both the preventive and adjuvant setting